### **Company Overview** Privi Speciality Chemicals Limited (PSCL) is India’s **leading manufacturer, supplier, and exporter of aroma and fragrance chemicals**, with over **three decades of experience** in the global flavours and fragrances (F&F) industry. Established in 1992, the company has evolved into a **vertically integrated, technology-driven specialty chemicals enterprise** that serves the world’s top 15 fragrance companies, including global giants like **Givaudan, Symrise, Firmenich, Procter & Gamble, and Reckitt Benckiser**. PSCL achieved independent listed status in 2021 following a demerger from Fairchem Speciality and has since established itself as a **preferred supplier to Fortune 500 and top-tier FMCG firms**. With **70% of revenue from exports** across more than **30 countries**, the company has a robust international footprint anchored in Europe, Asia, Latin America, and North America. --- ### **Core Business and Product Portfolio** Privi produces **over 75 specialty aroma chemicals**, with a strong focus on **pine-based, renewable, and high-performance molecules**. Its product portfolio is organized into four key segments: - **Pinene-based** (70% of sales): Dihydromyrcenol (DHMOL), Amber Fleur, Pine Oil, Terpineol, Camphor - **Citral-based**: Citral, Citronellal - **Phenol-based**: Phenol derivatives - **Specialty Aroma Chemicals**: Musk derivatives (e.g., Galaxmusk, Prionyl), Ionones, Sandal products, Indomerane, Floravone, Amber Woody Xtreme The company has recently expanded into **solid-form aroma chemicals**, such as **Prionyl**, of which it is **one of only three global manufacturers**, and continues to develop **high-complexity, low-volume molecules** for fine fragrances and premium personal care. --- ### **Competitive Advantages & Strategic Integration** #### **1. Backward Integration via CST & GTO** Privi is the **world’s largest single-site processor of Crude Sulphate Turpentine (CST)**, with a capacity of **36,000 MTPA**, derived as a **waste by-product from over 70 pulp and paper mills in North America and Europe**. This provides: - A **15–20% cost advantage** over Gum Turpentine Oil (GTO) - **Stable and sustainable supply chain**, insulated from volatile GTO markets dominated by China - One of only **four global companies** (and the **only one in Asia**) with the proprietary technology to extract **alpha and beta pinenes** from CST The company also maintains a **9,600 MTPA GTO processing capacity**, enabling dual sourcing for enhanced resilience. #### **2. Renewable Feedstock Innovation – ‘Waste to Wealth’ Model** - **CST from paper mills**: A **renewable, waste-derived feedstock** that supports ESG-compliant manufacturing - **Corn cob biorefinery**: Through **Privi Fine Sciences**, the company converts **corn cobs into furfural**, a green building block for **maltol, ethyl maltol, and cyclopentanone**—positioning it as **India’s first domestic manufacturer** of these chemicals and reducing reliance on Chinese imports - **Whole corn utilization**: Maximizing resource efficiency by **producing ethanol from kernels and furfural from cobs**, creating a closed-loop biorefinery #### **3. Proprietary Technologies & Capabilities** Privi’s R&D-driven model supports: - **Pine chemistry expertise** in hydrogenation, Grignard reactions, pyrolysis, and high-vacuum distillation - **Biotechnology development** (via Privi Biotechnologies): Fermentation and biotransformation for next-gen molecules like **menthol, peppermint oil**, and **bio-butanol** - **Green chemistry**: Development of low-carbon, renewable pathways for synthetic routes --- ### **Global Market Position & Customer Base** - **Supplier to all top 10 global F&F companies** and **six of the top FMCG firms** - **Exports to 38 countries**, with key stocking points in **Rotterdam, New Jersey, and Singapore** - **Distribution networks** in Grasse (France), Manchester (UK), Brazil, Mexico, and Shanghai - **70% of revenue from exports**, with only **7% exposure to the U.S. market**, minimizing tariff risk - **20%+ global market share in ten key products**, including **Dihydromyrcenol, Amber Fleur, and Galaxmusk** - Strong demand from **Africa, Middle East, and Asia** driven by **hygiene awareness and premiumization of consumer goods** --- ### **Joint Venture with Givaudan – PRIGIV** A landmark **51% (Privi)–49% (Givaudan)** joint venture, **Prigiv Specialties Pvt Ltd**, was launched to manufacture **40 high-complexity, exclusive fragrance ingredients** for Givaudan alone. Key details: - **Greenfield facility** in **Mahad, Maharashtra**, inaugurated **October 2024**, began **commercial production February 2025** - Total investment: **₹178 crores**, co-financed by equity and long-term loan from Givaudan - Features **custom-built, state-of-the-art equipment** for **low-volume, high-molecular-weight fragrances** - **Site expanded by 5 acres** for future capacity scaling - Expected to **ramp up over 2–3 years**, contributing to **long-term, stable revenue** and **higher EBITDA margins** - Represents **first JV Givaudan has entered with an Indian company**, affirming Privi’s **technical excellence and innovation capability** --- ### **Financial and Operational Performance (Nov 2025)** - **10 consecutive quarters of 24–26% YoY revenue growth**, driven by **strong demand, operational efficiency, and improved product mix** - **EBITDA margins consistently above 20%**, supported by **backward integration, yield optimization, and new product launches** - **Best-ever quarterly and half-yearly performance** reported in recent periods - **Capacity**: Total production exceeds **48,000 MTPA**, with a **3-phase expansion roadmap** aiming for **~50% capacity increase over 3–4 years** - **CAPEX**: Estimated **₹250–300 crores** planned by **March 2026** to de-bottleneck capacity and launch new products --- ### **Strategic Growth Initiatives** #### **1. Product Portfolio Diversification** - **Reducing reliance on any single product** – Target: **No product to contribute >10% of revenue** - **New launches (2023–2025)**: Camphor, Galaxmusk, Prionyl, Indomerane, Floravone, Amber Woody Xtreme - **Pipeline**: Over **40 products with PRIGIV**, **112 high-end specialty chemicals** in R&D - **Upcoming launches (FY26)**: Aphermate, Menthofuran, L-Camphor Sulphonic Acid, Privional (Helional), Pricyclal (Cyclal C) #### **2. Amalgamation of Group Companies** Privi plans to **amalgamate**: - **Privi Fine Sciences (green chemistry)** - **Privi Biotechnologies (biotech R&D)** - **Privi Speciality Chemicals Ltd** → To create a **single, synergized entity** with **integrated value chain**, enhanced R&D focus, and **scalable green innovation platform** #### **3. Sustainability & Regulatory Leadership** - **Zero Liquid Discharge (ZLD)** in key facilities - **70% of raw materials from renewable sources** - **REACH, IFRA, GHS, and US/EU FDA compliance** secured - **Pre-registered 26 products under Turkey’s KKDIK**, ensuring uninterrupted supply to EU/EEA markets until 2026 - **Natural hedge against INR-USD volatility** due to **~70% exports and imports**, minimizing forex risk --- ### **R&D and Innovation Infrastructure** - **91-member R&D team** across **Mahad and Nerul (Navi Mumbai)**, DSIR-recognized centers - **Pilot plants, GCMS, FTIR, and synthetic organic labs** enabling **"Concept to Commissioning" innovation** - **Focus areas**: - Capacity intensification - New product development - JV-specific projects (PRIGIV) - **Biorefinery partnership** with **ICT Mumbai** for fermentation-based specialty chemicals - **Natural-identical menthol** and **peppermint oil** at pilot scale; potential **₹400–600 crore capex plant** in future --- ### **Governance & Leadership** - **Chairman & MD: Mr. Mahesh P. Babani** – Over **36 years** in the industry, instrumental in building global relationships and driving strategic growth - Experienced **business unit leaders** with 20+ years in their domains - Strategic **private equity support** from **Standard Chartered, Avigo, and Fairfax** in past - **Target debt/equity ≤1x** and **debt/EBITDA <3x** over next 3–5 years, ensuring financial discipline